China SXT Pharmaceuticals, Inc. (SXTC) Gross margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) gross margin by fiscal year — reported gross profit divided by reported revenue.
21.9%FY2026 · since FY2017: 47.4% → 21.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 21.9% | +0.7 pp |
| FY2025 | 21.1% | -7.6 pp |
| FY2024 | 28.7% | +7.1 pp |
| FY2023 | 21.6% | -26.5 pp |
| FY2022 | 48.1% | -11.3 pp |
| FY2021 | 59.4% | +7.1 pp |
| FY2020 | 52.4% | -13.4 pp |
| FY2019 | 65.8% | +17.3 pp |
| FY2018 | 48.5% | +1.1 pp |
| FY2017 | 47.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Net marginSXTC Gross profitSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →